Readable research linked to original sources
Articles
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
Loading articles data…
Readable research linked to original sources
Browse normalized, publication-ready research with direct links to its evidence and source.
118 articles
Newest firstBackgroundCannabis use disorder affects a substantial proportion of the population and is often accompanied by mental health comorbidities, including depressive symptoms and problematic Internet use (PIU). This study explores the association between PIU and depressive symptoms among adults at high-risk of cannabis use disorder, a relationship insufficiently explored despite the high prevalence of these conditions…
Open article record in new tab ↗Background Educational attainment (EA), which comprises cognitive (CogEA) and noncognitive (NonCogEA) components, is positively genetically correlated with alcohol and cannabis use but negatively correlated with alcohol and cannabis use disorders (AUD and CUD). These paradoxical associations suggest that shared genetic influences with EA may differ by level of substance involvement. Methods To test this, we examin…
BACKGROUND: Indicated prevention targeting adolescents at psychosocial risk is a public health priority, yet evidence on its effectiveness in Spain remains limited. This study evaluates the impact of a preventive program on personality traits, personal competencies, psychopathological symptoms, cannabis use, and other risk behaviors. METHODS: A quasi-experimental design with three assessment points (pre-interventi…
Open article record in new tab ↗Comorbid substance use disorders (SUDs) are common but difficult to study due to the complex, interacting and overlapping mechanisms through which they affect brain networks. Many datasets collected to investigate a specific SUD include participants with comorbid SUDs. Although most studies treat comorbid SUDs as covariates of no interest, these covariates also contain untapped information. This is particularly re…
Open article record in new tab ↗BACKGROUND: Pain is one of the leading causes of disability worldwide. Despite the various pharmacological treatments available, patients with chronic pain often remain with significant disabilities and unsatisfactory pain control. Cannabis and cannabinoids are sometimes used in the treatment of chronic pain as they have been shown to be useful in a subset of patients. Some of the adverse effects associated with c…
Open article record in new tab ↗Background: Attention-Deficit/Hyperactivity Disorder (ADHD) in adulthood is frequently associated with complex psychiatric comorbidity, including high rates of Substance Use Disorders (SUDs), which may influence treatment outcomes. Although pharmacological treatments are effective for core ADHD symptoms, real-world response remains heterogeneous, and the contribution of specific substance-related and neurodevelopm…
Background In recent decades, the potency of cannabis resin increased globally, raising concerns, as higher potency has been associated with increased risk of psychiatric harms at the individual level. The aim here was to examine whether changes over time in the potency of seized cannabis resin samples were associated with psychiatric harms at the population level. Methods Data on ∆-9-tetrahydrocannabinol (THC) co…
Aim High-frequency repetitive transcranial magnetic stimulation (rTMS) targeting the dorsolateral prefrontal cortex (DLPFC) shows promise in treating substance use disorders, but its efficacy for cannabis use disorder (CUD) is less well established. This 12-month, two-phase, three-arm, prospective, open-label study evaluated the short- and long- term effects of high-frequency rTMS over the left DLPFC in individual…
Open article record in new tab ↗Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint. Abstinence, however, is difficult for many patients to attain, may not align with their treatment goals, and can obscure meaningful clinical improvements. By contrast, the al…
Open article record in new tab ↗Background Conventional psychological and pharmacological substance abuse treatments are limited to moderate effect sizes and fail to magnify outcomes when combined. Analog psychedelic agents N, N-dimethyltryptamine (DMT) and 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) show therapeutic potential for treatment-resistant psychiatric disorders including substance addictions. Methods This systematic review and meta-…
Objectives Cannabis is one of the most widely used psychoactive substances, and many adults meet the criteria for Cannabis Use Disorder (CUD). Prior research on its association with cardiovascular disease (CVD) has yielded mixed results. This study evaluates the relationship between CUD and CVD among ED patients. Methods This retrospective, propensity-matched analysis examined records from 67 US healthcare organiz…
Open article record in new tab ↗Rationale Cannabis use disorder (CUD) affects over 50 million people globally. Emerging evidence shows that some people with CUD may experience altered social cognition (e.g., emotion recognition or differentiation). These impairments can affect their ability to understand others' emotional states and navigate social interactions, potentially contributing to chronic cannabis use, even when it leads to interpersona…
Despite substantial progress in preclinical cannabinoid research, translational studies on cannabis use disorders (CUD) are still insufficient due to the absence of robust, validated animal models that fully recapitulate the multifactorial clinical phenotype of human CUD. The complex nature of CUD and the incomplete understanding of its underlying neurobiological mechanisms contribute to the limited availability o…
Background Cannabis use is increasing globally, with a parallel rise in Cannabis Use Disorder (CUD). Chronic pancreatitis (CP), a progressive inflammatory condition, is associated with acute pancreatitis (AP) flares and an elevated risk of pancreatic cancer (PC). Although cannabis is often used for pain management in CP, its impact on PC risk and AP flare frequency is unclear. Methods We conducted a retrospective…
Background A common feature of cannabis use disorder (CUD) is an intense reactivity to cannabis cues, which are becoming increasingly visible due to the growth in its decriminalization, accessibility, and marketing of cannabis products. The brain's automatic reactivity to cannabis cues can trigger craving and subsequent use. In this study, we aimed to test neural activity during cannabis cue reactivity in non-trea…
Open article record in new tab ↗Introduction As cannabis policies become more liberal, and products increasingly potent, it is important to monitor changes in rates of cannabis use and those at risk of harm. We used data from the largest national mental health survey in Australia to examine changes in prevalence, associations and comorbidity of past 12-month cannabis use and cannabis use disorder (CUD) from 2007 to 2020-22. Methods Data were dra…
Abstract:Introduction.Cannabis use is increasingly prevalent among patients with liver disease, its clinical impact on outcomes in cirrhosis remains unclear. This study evaluates the association between cannabis use disorder and clinical complications in patients with cirrhosis.Methods.We conducted a retrospective study using the TriNetX network. Adults aged 18-89 years with cirrhosis were divided into two cohorts…
Non-medical use of cannabis (NmC) and/or opioids (NmO) can lead to adverse health effects (AHEs), yet the proportion of these harms attributable to adverse childhood experiences (ACEs) remains unclear. This study estimated the contribution of ACEs to AHEs from NmC and/or NmO among adults aged ≥18 years using 2019-2020 Behavioral Risk Factor Surveillance System data from Arizona and Massachusetts. We conducted a re…
Background Cannabis use has increased across Europe over the last decade, accompanied by growing availability of high-potency THC products and rising psychiatric presentations. Despite these trends, European countries differ substantially in monitoring systems, clinical preparedness and public health responses. These disparities are especially visible between Western Europe, which has more developed pharmacovigila…
AbstractAimsCocaine use disorder prevalence is around 2.2% for individuals age 12 and older, with higher rates reaching 6.2% in young adults ages 18–25. In 2021, around 23% of all US overdose deaths were related to cocaine. Cannabis use disorder is more prevalent than cocaine use disorder with prevalence reaching 14.7%. This study aims to evaluate the impact of cocaine and cannabis on clinical cardiovascular outco…
Open article record in new tab ↗